瑞财经 刘治颖 9月22日，长风药业股份有限公司（以下简称：长风药业）通过港交所主板上市聆讯，中信证券、招银国际为其联席保荐人。招股书显示，长风药业主要专注于吸入技术及吸入药物的研发、生产及商业化，专注于治疗呼吸系统疾病。公司已开发出覆盖广泛患者、医学专科及治疗领域的产品组合。于往绩记录期间，公司自国家药品监督管理局（国家药监局）及美国食品药品监督管理局(FDA)获得六项产品批文并赚取大量销售收入...
Source Link瑞财经 刘治颖 9月22日，长风药业股份有限公司（以下简称：长风药业）通过港交所主板上市聆讯，中信证券、招银国际为其联席保荐人。招股书显示，长风药业主要专注于吸入技术及吸入药物的研发、生产及商业化，专注于治疗呼吸系统疾病。公司已开发出覆盖广泛患者、医学专科及治疗领域的产品组合。于往绩记录期间，公司自国家药品监督管理局（国家药监局）及美国食品药品监督管理局(FDA)获得六项产品批文并赚取大量销售收入...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.